RDY Stock Overview
Operates as an integrated pharmaceutical company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Dr. Reddy's Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹14.72 |
| 52 Week High | ₹16.89 |
| 52 Week Low | ₹12.26 |
| Beta | 0.34 |
| 1 Month Change | 5.75% |
| 3 Month Change | 15.18% |
| 1 Year Change | 7.16% |
| 3 Year Change | 33.19% |
| 5 Year Change | 38.76% |
| Change since IPO | 1,357.43% |
Recent News & Updates
Recent updates
Dr. Reddy's Continues To Be A Good Buy At Current Valuation
May 15Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns
Jan 30Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy
Aug 13Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements
Nov 29Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook
Oct 27Dr. Reddy's: Growth Supported By New Labels, Profitability
Aug 23Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy
Jun 07Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy
Feb 16Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed
Jan 20Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue
Nov 07Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M
Jul 28Dr. Reddy's launches generic drugs for allergies in US
Jul 22Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases
Jul 05Shareholder Returns
| RDY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.4% | 2.2% | 1.7% |
| 1Y | 7.2% | -9.6% | 11.5% |
Return vs Industry: RDY exceeded the US Pharmaceuticals industry which returned -10% over the past year.
Return vs Market: RDY underperformed the US Market which returned 12.5% over the past year.
Price Volatility
| RDY volatility | |
|---|---|
| RDY Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 11.3% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: RDY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RDY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 27,048 | Erez Israeli | www.drreddys.com |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Dr. Reddy's Laboratories Limited Fundamentals Summary
| RDY fundamental statistics | |
|---|---|
| Market cap | US$12.19b |
| Earnings (TTM) | US$660.92m |
| Revenue (TTM) | US$3.81b |
Is RDY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDY income statement (TTM) | |
|---|---|
| Revenue | ₹325.54b |
| Cost of Revenue | ₹135.11b |
| Gross Profit | ₹190.43b |
| Other Expenses | ₹133.88b |
| Earnings | ₹56.54b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 67.87 |
| Gross Margin | 58.50% |
| Net Profit Margin | 17.37% |
| Debt/Equity Ratio | 13.6% |
How did RDY perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/30 13:11 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dr. Reddy's Laboratories Limited is covered by 81 analysts. 36 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |